FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer
The FDA has approved Genentech's oral drug giredestrant, sold as Wilserdly, with everolimus for ESR1-mutated advanced breast cancer. In the evERA trial, median progression-free survival was 10 months versus 5.5 months, but overall survival data remain immature and the label is limited to ESR1-mutated disease.
FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy
The FDA has approved Genentech's Gazyva for adults with primary membranous nephropathy, a rare autoimmune kidney disease with no previously approved drug. In a 142-patient trial, complete remission at two years was far more common than with tacrolimus, an off-label standard option.